Kathy is recognized as a pioneer in precision medicine,[4] having seen its vast potential in oncology and other diseases. She uses her patient experience and business acumen to drive science faster with innovative business models across registries, big data, clinical trials, and venture. Kathy is a champion of patient engagement, encouraging each patient take initiative to optimize their own care.[5]
Kathy has been named one of
Time magazine's 100 Most Influential People in the world.[6] and ranked #19 on Fortune's list of Worlds' 50 Greatest Leaders.[7]
Career
Early career
Kathy held executive positions with increasing responsibility in consumer marketing with Gillette/Procter & Gamble and in the pharmaceutical sector of the healthcare industry with Merck & Co. and G.D. Searle & Company (now Pfizer).[8]
The Multiple Myeloma Research Foundation
In 1998, with her identical twin sister Karen Andrews, Kathy Founded the Multiple Myeloma Research Foundation (the MMRF). The MMRF’s mission is to accelerate a cure for each and every multiple myeloma patient.
As founder, president, CEO, and Chief Mission Officer Kathy has led the MMRF in establishing partnerships and collaborative research models in precision medicine including the Multiple Myeloma Research Consortium (MMRC), the MMRF CoMMpass™ study,[9] CureCloud, the Right Track, and the Myeloma Investment Fund.[10][11][12]
Under Giusti the MMRF has raised more than $500 million to fund research, 15 drugs have been approved to treat multiple myeloma, and many clinical trials are underway.[13] These efforts have accelerated the pace at which treatments are brought to patients and more than tripled patients' survival.[1]
Harvard Business School (HBS)
Giusti joined the Harvard Business School faculty as Senior Fellow, Co-Chairing the HBS Kraft Precision Medicine Accelerator, a $20 million endowed program provided by
Robert Kraft and the Kraft Family Foundation.[3]
The Kraft Accelerator has convened more than 300 leaders from throughout the healthcare and precision medicine ecosystem, from different disease states, and from the investment community. The Kraft Accelerator has identified and published best practices for accelerating cures and created The Kraft Precision Medicine Accelerator Playbook for Cures.[14]
Giusti has co-led the formation of the Kraft Accelerator Leadership Forum, a group of CEOs from disease-focused foundations working together to address the most important challenges, share best practices, and accelerate precision medicine models.
Diagnosis
In 1996, Kathy Giusti was diagnosed with multiple myeloma, an incurable blood cancer. When diagnosed, Giusti was 37 years old and was given three years to live. At the time of her diagnosis, there were no new treatments in the pipeline for multiple myeloma.[15] In 2022, Kathy was diagnosed with early-stage breast cancer as well.[16]
Appointments
Kathy has been appointed to multiple positions and advisory boards, all with a focus on developing cures for cancer. These include:
National Cancer Advisory Board (NCAB). Appointed by President George W. Bush. Served for six years during the Bush and Obama administrations.[9]
Precision Medicine Initiative (PMI) Working Group, appointed by President Obama[17]
Biden Cancer Initiative Advisory Committee and Biden Moonshot
National Institutes of Health All of US Research Program[17]
Kathy is recognized as a pioneer in precision medicine,[4] having seen its vast potential in oncology and other diseases. She uses her patient experience and business acumen to drive science faster with innovative business models across registries, big data, clinical trials, and venture. Kathy is a champion of patient engagement, encouraging each patient take initiative to optimize their own care.[5]
Kathy has been named one of
Time magazine's 100 Most Influential People in the world.[6] and ranked #19 on Fortune's list of Worlds' 50 Greatest Leaders.[7]
Career
Early career
Kathy held executive positions with increasing responsibility in consumer marketing with Gillette/Procter & Gamble and in the pharmaceutical sector of the healthcare industry with Merck & Co. and G.D. Searle & Company (now Pfizer).[8]
The Multiple Myeloma Research Foundation
In 1998, with her identical twin sister Karen Andrews, Kathy Founded the Multiple Myeloma Research Foundation (the MMRF). The MMRF’s mission is to accelerate a cure for each and every multiple myeloma patient.
As founder, president, CEO, and Chief Mission Officer Kathy has led the MMRF in establishing partnerships and collaborative research models in precision medicine including the Multiple Myeloma Research Consortium (MMRC), the MMRF CoMMpass™ study,[9] CureCloud, the Right Track, and the Myeloma Investment Fund.[10][11][12]
Under Giusti the MMRF has raised more than $500 million to fund research, 15 drugs have been approved to treat multiple myeloma, and many clinical trials are underway.[13] These efforts have accelerated the pace at which treatments are brought to patients and more than tripled patients' survival.[1]
Harvard Business School (HBS)
Giusti joined the Harvard Business School faculty as Senior Fellow, Co-Chairing the HBS Kraft Precision Medicine Accelerator, a $20 million endowed program provided by
Robert Kraft and the Kraft Family Foundation.[3]
The Kraft Accelerator has convened more than 300 leaders from throughout the healthcare and precision medicine ecosystem, from different disease states, and from the investment community. The Kraft Accelerator has identified and published best practices for accelerating cures and created The Kraft Precision Medicine Accelerator Playbook for Cures.[14]
Giusti has co-led the formation of the Kraft Accelerator Leadership Forum, a group of CEOs from disease-focused foundations working together to address the most important challenges, share best practices, and accelerate precision medicine models.
Diagnosis
In 1996, Kathy Giusti was diagnosed with multiple myeloma, an incurable blood cancer. When diagnosed, Giusti was 37 years old and was given three years to live. At the time of her diagnosis, there were no new treatments in the pipeline for multiple myeloma.[15] In 2022, Kathy was diagnosed with early-stage breast cancer as well.[16]
Appointments
Kathy has been appointed to multiple positions and advisory boards, all with a focus on developing cures for cancer. These include:
National Cancer Advisory Board (NCAB). Appointed by President George W. Bush. Served for six years during the Bush and Obama administrations.[9]
Precision Medicine Initiative (PMI) Working Group, appointed by President Obama[17]
Biden Cancer Initiative Advisory Committee and Biden Moonshot
National Institutes of Health All of US Research Program[17]